This summary is generated by an algorithm. If you find any mistakes, let us know.

Biotechnology Health Care Medical North America Pharmaceutical

Elligo Health Research Inks $135M Series E

– Elligo Health Research, a healthcare-enabling research organization powered by the novel IntElligo technology, announced a $135m Series E financing round.
Morgan Stanley Expansion Capital and Ally Bridge Group participated in the financing round.
– The round was also participated by Norwest Venture Partners and all major existing investors, including Cerner, Hatteras Venture Partners, Noro-Moseley Partners, Piper Sandler Merchant Banking, Shumway Capital, and Syneos Health.
– This financing allows Elligo to invest further in its technology platform and leverage data in new ways to address current challenges in the clinical trial industry.

Source
Biopharma Biotechnology Health Care North America Pharmaceutical

Credence MedSystems Raises $39.9M in Funding

– Credence MedSystems, a Menlo Park, CA-based provider of drug delivery systems, raised $39.9M in funding.
– The round was led by Novartis Pharma AG and Molex Ventures LLC.
– The investment will be directed towards scaling of production capacity for the Credence Companion® and Dual Chamber Reconstitution Systems as well as development of other members of the company’s platform of innovative drug delivery systems, including its connected health portfolio.

Source
Biotechnology Health Care North America Pharmaceutical

858 Therapeutics Launches with Proven Team and $60 Million Series A Financing

– 858 Therapeutics has raised $60m in Series A financing.
– The round was led by founding investor Versant Ventures, with participation from NEA, Cormorant Asset Management and Logos Capital.
– 858 is a biotechnology company developing novel therapeutics for the treatment of cancer.
– The company’s lead program is a novel small molecule inhibitor of the PI3K/mTOR pathway that is being developed for the treatment of solid tumors that are resistant to existing therapies.
– The Series A proceeds will allow 858 to enter the clinic with its lead candidates that have potential to treat cancers that are resistant to current therapies.

Source
Biotechnology Life Science Manufacturing North America Pharmaceutical

SmartLabs Announces $250 Million Series B and Update of Proprietary Laboratory OS

– SmartLabs, a Boston-based Laboratory-as-a-Service (LaaS) leader, announced the raise of a $250m Series B financing.
– The funding round was led by ArrowMark Partners. New investment partners include Winslow Capital Management and Onex Falcon, joined by existing investors Conversion Venture Capital (CVC2) and Breed’s Hill Capital.
– The funding will fuel the company’s accelerated growth, with a plan to scale operations to 2m sq ft within five years.
– In addition, SmartLabs announced the launch of the fourth version of its proprietary laboratory operations system (SmartLabs OS) which was first pioneered and introduced in 2016.

Source
Biotechnology Health Care Medical Pharmaceutical Therapeutics Wellness Western Europe

Amolyt Pharma Raises $80M in Series B Financing

– Amolyt Pharma from Lyon develops therapeutic peptides for rare endocrine and related diseases.
– The company closed an $80m Series B round.
– The round was co-led by Sectoral Asset Management and Andera Partners, with participation from ATEM Capital, LSP, Novo Holdings (Novo Ventures), Kurma Partners, Mass General Brigham Ventures, Innobio 2 managed by Bpifrance, Orbimed, Pontifax, Eurazeo, Sham Innovation Santé/Turenne Capital and Credit Agricole Creation.
– The company plans to use the proceeds from the financing to advance its pipeline of potential therapeutics for rare endocrine and related diseases, including clinical development of AZP-3601 for hypoparathyroidism, pre-clinical development of AZP-3813 for acromegaly and ongoing research related to AZP-3404, and to further expand its early-stage pipeline through both internal research and development activities and potential in-licensing opportunities.

Source
Biotechnology Health Care Medical Pharmaceutical Therapeutics Wellness Western Europe

Amolyt Pharma Raises $80M in Series B Financing

– Amolyt Pharma from Lyon develops therapeutic peptides for rare endocrine and related diseases.
– The company closed an $80m Series B round.
– The round was co-led by Sectoral Asset Management and Andera Partners, with participation from ATEM Capital, LSP, Novo Holdings (Novo Ventures), Kurma Partners, Mass General Brigham Ventures, Innobio 2 managed by Bpifrance, Orbimed, Pontifax, Eurazeo, Sham Innovation Santé/Turenne Capital and Credit Agricole Creation.
– The company plans to use the proceeds from the financing to advance its pipeline of potential therapeutics for rare endocrine and related diseases, including clinical development of AZP-3601 for hypoparathyroidism, pre-clinical development of AZP-3813 for acromegaly and ongoing research related to AZP-3404, and to further expand its early-stage pipeline through both internal research and development activities and potential in-licensing opportunities.

Source
North America Pharmaceutical

Bantam Pharmaceutical Closes $25M Seed Funding

– Bantam Pharmaceutical is a Research Triangle Park, N.C.-based drug discovery and development company targeting selective modulation of mitochondrial dynamics in cancer.
– The company raised $25m in seed funding.
– The round was co-led by current investors including Lionel Goldfrank, who also is a board member.
– The new investment will be used to finalize its ongoing IND-enabling activities for its lead program, BTM-3566, and consummate preparations for first in human clinical trials.

Source
Biotechnology Eastern Asia Pharmaceutical

IASO Biotherapeutics Secures $108 Million Series C Funding to Advance Global Development of Innovative Cell Therapies

– IASO Biotherapeutics announced the completion of $108m Series C to advance the global development of novel cell therapies and biologics for oncology and autoimmune diseases.
– The round was led by CDH Baifu, and followed by CCB International, with strong participation from Everbright Limited, Co-Stone Capital, CNCB Capital and Plaisance Capital.
– Current shareholder GL Ventures also participated.
– Since its founding in 2017, IASO Bio has raised more than $178m.
– Proceeds from the financing will be used to accelerate the global development and regulatory submissions of multiple novel cell therapies.

Source
Biotechnology Pharmaceutical Western Europe

Anjarium Biosciences Raises $61M in Series A Financing

– Anjarium Biosciences AG is a Schliren, Zurich-based biotech company focused on creating and delivering a new class of non-viral gene therapies.
– Series A funding closed at $61m.
– The round was co-led by Abingworth and Gimv, with participation from Omega Funds, Pfizer Ventures and Surveyor Capital (a Citadel company).
– The new investment will be used to advance the company’s pipeline programs towards clinical development.

Source
Biotechnology Pharmaceutical Western Europe

Anjarium Biosciences Raises $61M in Series A Financing

– Anjarium Biosciences AG is a Schliren, Zurich-based biotech company focused on creating and delivering a new class of non-viral gene therapies.
– Series A funding closed at $61m.
– The round was co-led by Abingworth and Gimv, with participation from Omega Funds, Pfizer Ventures and Surveyor Capital (a Citadel company).
– The new investment will be used to advance the company’s pipeline programs towards clinical development.

Source
Biotechnology Health Care North America Pharmaceutical

ROME Therapeutics Secures $77 Million in Series B Financing to Advance Repeatome-derived Pipeline for Cancer and Autoimmune Diseases and Expand Repeatomics Platform

– ROME Therapeutics announced the completion of a $77m Series B financing round.
– The round was led by new investor Section 32 and included participation from Sanofi Ventures, Casdin Capital, Andreessen Horowitz and Alexandria Venture Investments.
– ROME’s mission is to harness the power of the repeatome – the roughly 60% of the human genome consisting of repetitive sequences of nucleic acids, known as repeats – to discover powerful new classes of medicines for cancer and autoimmune diseases.
– ROME has identified multiple repeatome-derived targets and created an internal data science platform, called repeatomics, to analyze vast quantities of data available through the repeatome.

Source
Analytics Artificial Intelligence Australia and Oceania Big Data Health Care Information Technology Machine Learning Pharmaceutical Predictive Analytics

Prospection Secures $45 million to Accelerate Growth of its Powerful Healthcare Insights Technology

– Prospection has successfully raised $45m from institutional investors in a Series B round, cornerstoned by new investor Ellerston JAADE with participation from existing shareholders Main Sequence and Horizons Ventures.
– Prospection uses real world data, powering evidence to deliver better patient outcomes. Its powerful AI algorithms follow millions of de-identified patients over time to search for patterns in their health and treatment journey. Uniquely, these algorithms can ingest multiple longitudinal patient and commercial datasets globally from varied sources such as governments, insurers, healthcare providers/institutions and health records, to produce rich and accurate insights at high speed.
– These datasets are turned into actionable, medical insights to help determine the best treatment plan for a patient, locate patients who would benefit from improved therapeutic decisions and be written into publishable evidence for scientific journals.

Source
Biotechnology Health Care North America Pharmaceutical

Obsidian Therapeutics Closes $115M Series B Financing

– Obsidian Therapeutics, Inc. is a Cambridge, Mass.-based biotechnology company pioneering engineered cell and gene therapies.
– The company closed a $115m Series B financing.
– The round was led by The Column Group Crossover Fund (TCGX) with participation from RA Capital Management, Surveyor Capital (a Citadel company), Cowen Healthcare Investments, Deep Track Capital, Logos Capital, Pivotal BioVenture Partners, Samsara BioCapital, and Soleus Capital, and existing investors Atlas Venture, Vertex Ventures HC, Amgen Ventures, and Bristol Myers Squibb.
– Proceeds from the financing will be used to drive Obsidian’s lead tumor infiltrating lymphocyte (TIL) program, cytoTIL15, into the clinic and to first clinical data for the treatment of metastatic melanoma. In addition, the company plans to rapidly expand cytoTIL15 into multiple other solid tumor types and to advance its commercial manufacturing build.

Source
Life Science Pharmaceutical Western Europe

Provepharm Life Solution Raises €120M in Funding

– Provepharm Life Solutions, a Marseille-based pharmaceutical company that finds new applications for known molecules.
– The company raised €120M in funding.
Tikehau Capital will provide the funds joining the group’s pool of banking investors, including Société Générale, BNP Paribas, Banque Populaire Méditerranée, Crédit Agricole Alpes Provence and Bpifrance.
– The new investment will be used to consolidate its position as an international and independent pharmaceutical group, specifically by hiring new staff in France and the United States, and increasing the size of its laboratories in Marseille.

Source
Medical North America Pharmaceutical

CaaMTech Raises $22M in Series A Funding

– CaaMTech is a psychedelic drug discovery company.
– The company raised $22M in Series A funding.
– The round was led by Noetic Fund.
– The new investment will be used to support the company’s cross-disciplinary science program, expand its leadership team, and advance its foremost drug development candidates into human trials.

Source
Biotechnology Health Care Medical North America Pharmaceutical

ADARx Raises $75 Million to Advance Growing Pipeline

– ADARx Pharmaceuticals, Inc. completed a $75m Series B financing.
– The round was co-led by SR One Capital Management and OrbiMed Advisors.
Sirona Capital joined this financing as well as existing investor Lilly Asia Ventures.
– The proceeds from the Series B financing will be used to advance ADARx’s proprietary RNA platform technologies for base editing, inhibition, degradation, and delivery.
– The proceeds will also be used to transition ADARx’s growing pipeline of research phase products into the clinic including initiation of a Phase 1 clinical trial for ADARx’s lead program.

Source
Biotechnology Genetics Health Diagnostics North America Pharmaceutical

bluebird bio Secures $75 Million in Private Placement Equity Financing

– bluebird bio, Inc. announced that it has entered into an agreement for a $75m private placement of common stock and common stock equivalents with a healthcare investment fund selected as part of a competitive process.
– Proceeds from the financing will support ongoing R&D and commercialization investments for bluebird bio and for 2seventy bio, which plan to launch as independent companies in October 2021.
– bluebird plans to complete the spin-off of 2seventy in October 2021, subject to customary conditions, including effectiveness of the Form 10, a favorable opinion from the IRS with respect to the tax-free nature of the transaction, and final approval from bluebird’s Board of Directors.

Source
Biopharma Health Care Medical North America Pharmaceutical

ARS Pharmaceuticals Raises $55M in Series D Funding

– ARS Pharmaceuticals, a San Diego CA-based pharmaceutical company, raised $55M in Series D funding.
– The round was led by SR One with participation from RA Capital Management and Deerfield Management.
– The company intends to use the funds to advance Neffy through approval, to support initial launch activities, and to evaluate it in clinical studies for additional indications.

Source
Health Care Medical Device North America Pharmaceutical

Onkos Surgical Raises $15 Million in Series C Funding

– Onkos Surgical has raised $15m in Series C funding from its existing investor syndicate.
– The new funding will drive revenue growth by accelerating the company’s research and development pipeline, expanding its commercial footprint, and evolving manufacturing capabilities.
– These investments support the company’s focus on delivering surgeon-driven and patient-inspired approaches to address three main clinical challenges of complex orthopaedic procedures – implant loosening, soft tissue failures, and infection.

Source
Biotechnology Life Science Medical North America Pharmaceutical

Versanis Bio Raises $70M in Series A Financing

– Versanis Bio is an Oakland, Calif.-based company established to discover and develop first-in-class medicines that address medical conditions prevalent in older adults.
– The company closed a $70m Series A financing.
– The round was co-led by Atlas Venture and Medicxi with participation from Aditum Bio.
– The company intends to use the funds to advance a comprehensive phase 2 clinical program to evaluate the potential of bimagrumab to help obese patients lose fat and achieve an improved body composition.

Source
Biotechnology Eastern Asia Health Care Pharmaceutical

Lynk Pharmaceuticals Closes $50M Series B Financing

– Lynk Pharmaceuticals is a Hangzhou, China-based pharmaceutical R&D company.
– The company completed Series B financing of $50m.
– The round was led by Lilly Asia Ventures (LAV) with participation from New Alliance Capital and Hangzhou HEDA Biological Medicine Venture Capital Partnership (L.L.P.) and its original shareholders Legend Capital and Med-Fine Capital.
– The new investment will be used to conduct Phase I and II clinical trials for multiple programs in the R&D pipeline, expand international business, strengthen international collaborations with companies and support preclinical development of new projects.

Source
Biotechnology Health Care Health Diagnostics North America Pharmaceutical

Neurogastrx Secures $60 Million in Series B Financing and Expands Management Team to Advance Its Pipeline of Transformative Investigational Therapies for Gastrointestinal Disorders

– Neurogastrx, a privately held specialty pharmaceutical company developing transformative therapies for gastrointestinal (GI) disorders, announced the successful completion of a $60m Series B crossover round led by Vivo Capital.
– Other new investors participating in the Series B round include RTW Investments, Samsara BioCapital and Marshall Wace, joining 5AM Ventures, venBio and OrbiMed Advisors.
– Proceeds from the financing will be used to advance the company’s pipeline of GI therapies for serious conditions that impact millions of people yet are not effectively treated.

Source
Biopharma Biotechnology Pharmaceutical Western Europe

Cardior Raises €64M in Series B Funding

– Cardior Pharmaceuticals from Hanover develops non-coding RNA (ncRNA)-based therapeutics for patients with cardiac diseases.
– The company closed a €64m ($76m) Series B financing round.
– The round was led by Inkef Capital, supported by fellow new investors Fund+, Sunstone, Hadean Ventures and Coparion with participation from existing investors including LSP, BioMedPartners, Bristol Myers Squibb and High-Tech Gründerfonds.
– The new investment will be used for the late-stage clinical development of its lead program and the expansion of its earlier-stage pipeline.

Source
Health Care Medical Device North America Pharmaceutical

Checkpoint Surgical Completes $16M Equity Financing to Fuel Growth and Launch New Products

– Checkpoint Surgical, Inc. completed a $16m capital raise led by River Cities Capital, a Cincinnati-based healthcare-focused growth equity firm.
– Existing backers also participated in the round, including Cleveland-based venture funds Mutual Capital Partners and JumpStart NEXT Fund, First Analysis, a growth equity firm based in Chicago, and several other investors.
– The growth capital will be used to support Checkpoint’s sales force expansion and multiple new product launches, including the recently acquired NeuroShield nerve wrap, as well as fueling continued research and development efforts.
– With a specialized, dedicated sales force of 30 and growing, and a substantial multi-disciplinary R&D team, Checkpoint Surgical is well equipped to scale the business rapidly.

Source
Health Care Medical Pharmaceutical Western Europe

Beckley Psytech Closes $80M Series B Funding

– Beckley Psytech an Oxford, England-based private company dedicated to addressing neurological and psychiatric disorders through the novel application of psychedelic medicines closed an $80m Series B financing.
– The round was led by Integrated with participation from Prime Movers Labs, Adage Capital Management, Palo Santo; Delphi VC; Leafy Tunnel; Negev Capital; and existing investor Bicycle Day Ventures.
– The company intends to use the funds to complete the ongoing Phase 1b trial with low-dose psilocybin in patients suffering from SUNHA, a rare and debilitating headache condition estimated to affect 45,000 people in the US and Europe, and to initiate a Phase 1 dose-ranging study on a novel formulation of intranasal 5-MeO-DMT before starting a Phase 2 trial in Treatment Resistant Depression, and expand its pipeline with new, unique and proprietary psychedelic compounds.

Source
Information Technology North America Pharmaceutical

PBS Biotech Raises $10M in Funding

– PBS Biotech from Camarillo, CA is a manufacturer of single-use bioreactor systems.
– The company closed a $10M funding round.
– The investment was led by BroadOak Capital Partners.
– The new investment will be used to expand and industrialize the company’s portfolio of single-use bioreactor systems and contract process development services.

Source
Artificial Intelligence Big Data Biotechnology Clinical Trials Enterprise Enterprise Software Health Care Life Science Machine Learning North America Pharmaceutical

Intelligencia Raises $12M to Reduce the Risk of Clinical Research, Improve R&D Productivity, and Accelerate Scientific Breakthroughs

– Intelligencia, whose AI-driven software platform enables pharmaceutical and biotechnology companies to revolutionize the drug development process and reduce risk, has raised $12M in order to continue to expand its product offering and customer base.
– Healthtech investor MTIP led the oversubscribed Series A round, joined by several of the company’s existing investors, including Big Pi Ventures and Synetro Group. ZS, a global professional services firm that leverages deep analytics and biopharmaceutical industry expertise to help companies and their customers thrive, has also participated in this round.
– The company’s founders, Dimitrios Skaltsas and Vangelis Vergetis, met while at McKinsey & Company, and have spent more than a decade in the intersection of clinical development, data science, and technology solutions.

Source
Manufacturing North America Pharmaceutical

Sydnexis Secures $45 Million Series B Financing Led by Visionary Ventures and Blue Stem Capital

– Sydnexis, Inc. completed a $45m Series B financing led by Visionary Ventures, Blue Stem Capital, and SC Master Fund, with participation from existing investors RA Capital Management, Longitude Capital, and Medicxi.
– The financing will be used to fund Sydnexis’ lead candidate, SYD-101, through completion of the fully enrolled pivotal Phase 3 STAAR study for the treatment of progressive myopia in children.
– Sydnexis’ STAAR study is the largest pediatric myopia study globally to investigate the use of low dose atropine to retard progressive myopia. In this study, Sydnexis is evaluating two different concentrations of its proprietary atropine formulation SYD-101 (0.01% and 0.03%) versus a placebo control group.

Source
Biotechnology Life Science North America Pharmaceutical

Navrogen Raises $3.0M in Seed Funding

– Navrogen, Inc. from Cheyney, Pa. raises $3.0M in equity financing.
– The financing was led by Tellus BioVentures along with existing investors.
– The company intends to use the funds to advance its Humoral Immuno-Oncology (HIO) discovery platform and preclinical therapeutic pipeline activities.

Source
Biotechnology Eastern Asia Pharmaceutical

Zentera Therapeutics Raises $75M in Series b Funding

– Zentera Therapeutics, a Shanghai, China-based clinical-stage biopharmaceutical company, raised $75M in Series B funding.
– The round was led by OrbiMed Advisors Asia and Tybourne Capital Management with participation from Avidity Partners, Casdin Capital, Surveyor Capital, Farallon Capital Management, Lilly Asia Ventures, Logos Capital, Perceptive Advisors, Redmile Group and Viking Global Investors.
– The company intends to use the funds to advance the development of three Zentalis-discovered oncology clinical candidates as well as business development for future pipeline additions in China.

Source
Health Care Life Science Medical North America Pharmaceutical

Engrail Therapeutics Extends Series A Financing to $64 Million

– Engrail Therapeutics announced the close of a $32m Series A extension round bringing total investment in the company to $64m.
– The round was led by Nan Fung Life Sciences following their leadership of the original Series A raise.
– The Company will use the proceeds to finance the advancement of its diverse pipeline, including lead assets ENX-101, ENX-102 and internal preclinical programs.
– Engrail’s lead compounds are subtype-selective GABA-A modulators with compelling pharmacological profiles that possess wide ranging therapeutic utility.
– Engrail has assembled a diverse portfolio of assets with validated mechanisms through its dynamic model for advancing drugs aimed at treating life-limiting diseases of the nervous system.

Source
Biotechnology Medical North America Pharmaceutical

Aristea Therapeutics Closes $63M Series B Financing

– Aristea Therapeutics, a San Diego, CA-based clinical-stage immunology focused drug development company developing novel therapies to treat serious inflammatory orphan diseases, closed a $63m Series B financing.
– The round was led by Fidelity Management & Research Company, with participation from existing investor Novo Holdings A/S and new investors Arena Pharmaceuticals and funds managed by Tekla Capital Management.
– The company intends to use the funds to continue the build-out of its leadership team, the formation of new partnerships and the advancement of the development of its portfolio of immunology focused programs to address orphan diseases.

Source
Health Care North America Pharmaceutical Therapeutics

Surface Ophthalmics Raises $25M in Funding

-Surface Ophthalmics, a Pleasanton CA-based pharmaceutical company, raised $25M in funding.
– The round was led by both new and existing investors made up of institutional, healthcare-focused, and other accredited investors, including members of the Surface Board of Directors.
– The company intends to use the funds to advance its clinical programs in ocular diseases.

Source
Biotechnology Electronic Health Record (EHR) Health Care Health Insurance North America Personal Health Pharmaceutical

b.well Connected Health Raises $32M in Series B Funding

– b.well Connected Health is a digital transformation platform for healthcare.
– The company raised $32m in Series B financing round.
– The round was led by HLM Venture Partners (HLM) with participation from existing backers ThedaCare, UnityPoint Health Ventures, and Well Ventures–a subsidiary of Walgreens Boots Alliance, Inc.
– The new investment will be used to increase market penetration and advance product innovations.

Source
Artificial Intelligence Diabetes Health Care Health Diagnostics Hospital Medical Medical Device North America Personal Health Pharmaceutical

Eyenuk Raises $6.2M in Funding

– Eyenuk, a Los Angeles CA-based artificial intelligence (AI) medical technology and services company, raised $6.2M in funding.
– The round was led by AXA IM, through AXA IM Alts.
– The company intends to use the funds to accelerate commercialization of the EyeArt® AI System.

Source
Biotechnology Medical Neuroscience North America Pharmaceutical

Amylyx Pharmaceuticals Raises $135M in Series C Financing

– Amylyx Pharmaceuticals, Inc. closed $135m in Series C financing.
Viking Global Investors led the round with participation from Bain Capital Life Sciences, Perceptive Advisors, Rock Springs Capital, Woodline Partners, Marshall Wace, Tybourne Capital Management, Verition Fund Management, aMoon Fund and Falcon Edge.
– The company intends to use the funds for the clinical development and potential launch plans for lead product candidate AMX0035, for the potential treatment of ALS, and further research and development in other neurodegenerative diseases.

Source
Manufacturing Pharmaceutical Western Europe

Reacta Biotech Raises £2.9M in Funding

– Reacta Biotech from Deeside, North Wales, UK, raised £2.9m in funding.
– The round was led by Praetura Ventures with participation from existing shareholders including the Development Bank of Wales, Perscitus, Jon Moulton’s family office, and Reacta’s management team.
– The new investment will be used to scale up the company’s current product range, expand its team of specialists and expedite work on enhanced packaging solutions.

Source
Clinical Trials Health Care Medical Pharmaceutical Software Therapeutics Western Europe

Castor Raises $45M Series B to Modernize the Clinical Trial Process and Maximize the Impact of Research Data on Patient Lives

– Castor, a leading provider of clinical trial software, announced the closing of a $45m Series B financing round.
– The round, led by Eight Roads Ventures and F-Prime Capital with participation from existing investors Two Sigma Ventures and Inkef Capital, will fuel continued product development with a particular focus on scaling direct-to-patient trials globally.
– Most clinical trials today require a long set-up time and are conducted at brick-and-mortar research sites which make trial participation inconvenient for patients and leave researchers in the dark about patient data in-between site visits.

Source
Health Care North America Pharmaceutical Wellness

Genexa, the World’s First and Only Clean Medicine Company, Announces Record-breaking Series A Round

– Genexa, the world’s first clean, over-the-counter pharmaceutical company, has just completed its unprecedented $60m Series A of funding to advance its market leadership in this emerging space.
– Marking a seminal development in the consumer healthcare industry, Genexa’s oversubscribed campaign was the largest Series A ever raised for an OTC medicine company, substantiating the dramatic shift of consumers looking for cleaner options.
– Initially seeking $25m in capital, Genexa upsized the round because of the caliber of the investors and celebrities that wanted to be involved in spearheading the creation of a cleaner and more transparent medicine aisle.

Source
Biotechnology Genetics Life Science Pharmaceutical Western Europe

MiNA Therapeutics Receives $15M Equity Investment from Eli Lilly and Company

– MiNA Therapeutics Limited is a London, UK-based provider of small activating RNA therapeutics.
– Company received $15m equity investment from Eli Lilly and Company.
– The funds will be used to advance and expand its internal pipeline of saRNA therapeutics.

Source
Biotechnology Health Care Health Diagnostics Life Science North America Pharmaceutical

Xilis Raises $70 Million Series A Financing to Advance Diagnostic and Drug Discovery and Development Platform Leveraging Proprietary MicroOrganoSphere™ Technology

– Xilis, Inc. announced the close of a $70m Series A financing.
– The round was led by Mubadala Capital and joined by new investors including GV, LSP, Catalio Capital Management, and Duke Angel Network.
– Current investors Felicis Ventures, Two Sigma Ventures, Pear VC, KdT Ventures, and Alix Ventures also participated.
– Xilis is based on decades of biomedical, oncology, and stem cell research by its three co-founders.
– Dr. Clevers, a Breakthrough Prize winner, is the inventor and pioneer of the organoid technology.
– Dr. Shen and Dr. Hsu are accomplished engineering and medical professors at Duke University and experts in precision medicine.

Source
Artificial Intelligence Biotechnology Eastern Asia Health Care Machine Learning Pharmaceutical

Standigm Secures $10 M From Pavilion Capital to Accelerate Its Global Competitiveness

– Standigm has secured a $10m investment from Pavilion Capital for the clinical research of AI-driven drug compounds to strengthen the company’s competitiveness in the global market.
Pavilion Capital focuses on private equity and venture capital funds and direct investments in companies that ride on the growth and transformation of the North Asia and Southeast Asia economies.
Pavilion Capital pursues investments across different sectors, particularly in innovative technology and healthcare.
– The investment will be used for the clinical research of AI-driven drug compounds to strengthen the company’s competitiveness in the global market.

Source
Biotechnology Life Science North America Pharmaceutical

Psilera Raises $2.5M in Seed Funding

– Psilera Inc., formerly Psilera Bioscience, a Tampa, FLA.-based biotechnology company specializing in the clinical development of psychedelics and analogues, raised $2.5m in seed funding.
– The round was led by Iter Investments with participation from Baird, Inc., JLS Fund, Receptor, What If Ventures, as well as the company’s Founders and Board of Directors.
– The company intends to use the funds for key scientific and clinical personnel hires, research, and general working purposes.

Source
Health Care Management Information Systems North America Pharmaceutical

4G Clinical Announces $230MM Growth Equity Investment Backed by Goldman Sachs Asset Management

– Aera technology announced a growth equity investment of over $230M.
– The round was led by Goldman Sachs Asset Management (“Goldman Sachs”).
– The investment will be used to fund 4G Clinical’s continued global expansion, support the growing demand for 4G’s products, and to further the company’s mission of bringing crucial medicines to those who need them, faster.

Source
Biometrics Biotechnology Eastern Asia Pharmaceutical

Sanyou Biopharmaceuticals Raises Undisclosed Series B Funding

– Sanyou Biopharmaceutical, a Shanghai, China-based antibody drug discovery company, raised a Series B funding round of undisclosed amount.
– The round was led by LH Ventures and Montesy Investment, with participation from Grand Mount Capital and Seeking Capital.
– The new investment will be used to expand the company’s business reach.

Source
Biotechnology Clinical Trials Health Care North America Pharmaceutical

Lyndra Therapeutics Closes $60.5M Series C Financing

– Lyndra Therapeutics from Watertown, MA develops a novel technology platform that transforms daily pills into once-weekly to monthly oral treatment options.
– The company closed a $60.5m Series C financing round.
– The round was led by new investor, AIG Investments, an affiliate of American International Group with participation from new investors Yipinhong Pharmaceutical (USA) Limited, Limitless Ventures and the Catalytic Impact Foundation with ImpactAssets, and existing investors Polaris Partners, Invus, Quark Venture, Mass General Brigham Ventures, HOPU Investments, and Gilead Sciences, Inc.

Source
3D Printing Eastern Asia Pharmaceutical

Triastek Closes US$50M Series B Financing

– Triastek, Inc. is a Nanjing, China-based global leader in 3D printed pharmaceuticals.
– The company raised $50m in Series B funding.
– This round was co-led by Matrix Partners China and CPE with participation from Shanghai Sci-Tech Innovation Center Capital (SSICC) and existing investors.
– Triastek intends to use the funds for ongoing development of the first IND-approved product in clinical trials, and expansion of the 3D printed drug product pipeline.

Source
Biotechnology North America Pharmaceutical Therapeutics

Glycomine Closes $68 Million Series B to Advance into Clinical Trials a Novel Treatment for PMM2-CDG, a Rare Glycosylation Disease

– Glycomine, Inc. closed a $68m Series B financing.
– The proceeds of the financing will be used to advance Glycomine’s lead drug candidate, GLM101, through initial clinical trials in patients.
– GLM101 is a novel substrate replacement therapy in development to treat phosphomannomutase 2-congenital disorder of glycosylation (PMM2-CDG), a rare disease representing a critical unmet medical need.
– The Series B financing includes $35m of new funds in addition to the $33m announced in August 2019.
– Today’s financing was led by new investors, Abingworth and Sanofi Ventures, and joined by RiverVest Venture Partners and Remiges Ventures.

Source
Biotechnology Health Care North America Pharmaceutical

Tvardi Therapeutics Raises $74M in Series B Financing

– Tvardi Therapeutics, Inc. from Houston, Texas is a clinical-stage biopharmaceutical company focused on the development of STAT3 inhibitors.
– The company closed a $74m Series B funding.
– The round was led by new investors Slate Path Capital, Palkon Capital, ArrowMark Partners, and 683 Capital with participation from existing investors including Sporos Bioventures.
– The new investment will be aimed at advancing its product candidates through multiple clinical data readouts in mid-stage trials for cancer and fibrosis.

Source
Biotechnology North America Pharmaceutical Therapeutics

Enveda Biosciences Closes $51M Series A Financing Led by Lux Capital

– Enveda Biosciences announced an oversubscribed $51M Series A funding round.
– The financing was led by Lux Capital with participation from Two Sigma Ventures, Hummingbird VC, Catalio Capital, Lifeforce Capital, and Matthew De Silva of Notable Labs along with existing investors True Ventures, Wireframe Ventures, Village Global, and Chris Gibson of Recursion.
– Nature is the greatest source of therapeutics we know, yet 95 percent of the natural world is a chemical mystery. Enveda is systematically exploring this unknown space to unlock its potential for new medicines with the first high-resolution chemical map of the natural world.
– This new investment will further power Enveda’s data-driven approach to screening, validating, and developing high-potential natural compounds into first-in-class clinical candidates.

Source
Artificial Intelligence Biotechnology Eastern Asia Genetics Health Care Pharmaceutical

Insilico Medicine Raises $255 Million in Series C Financing Led by Warburg Pincus

– Insilico Medicine announced that it has closed a $255m Series C.
– The financing led by Warburg Pincus, and participated by current investors including Qiming Venture Partners, Pavilion Capital, Eight Roads Ventures, Lilly Asia Ventures, Sinovation Ventures, BOLD Capital Partners, Formic Ventures, Baidu Ventures, and new investors including CPE, OrbiMed, Mirae Asset Capital, B Capital Group, Deerfield Management, Maison Capital, Lake Bleu Capital, President International Development Corporation, Sequoia Capital China and Sage Partners.
– The financing will be used to progress Insilico Medicine’s current therapeutic programs into human clinical trials, initiate multiple new programs for novel and difficult targets, and further develop its AI and drug discovery capabilities.

Source
Biopharma Biotechnology Medical Pharmaceutical Southeast Asia

Nuevocor closes US$24M Series A Financing to Advance Novel Gene Therapies for Cardiomyopathies

– Nuevocor has announced the completion of an oversubscribed $24m Series A financing round.
– The round was co-led by EVX Ventures and Boehringer Ingelheim Venture Fund (BIVF), with EDBI, Xora Innovation, SEEDS Capital and other investors joining the syndicate.
– Funds will be used to accelerate the preclinical development of its lead programme, an adeno-associated virus (AAV) – based gene therapy for patients suffering from dilated cardiomyopathy (DCM) due to mutations in the lamin A/C (LMNA) gene.

Source
Biotechnology Medical North America Pharmaceutical Therapeutics

Veralox Therapeutics Closes $16.6M Series A Financing

– Veralox is a biotechnology company developing first-in-class small molecule therapeutics that treat the underlying pathologies of diseases with significant unmet medical needs, closed a $16.6m Series A financing.
– The round was led by Hatteras Venture Partners with participation from Genesys Capital, Point Field Partners and Alexandria Venture Investments as well as support from previous investors Sanofi Ventures, JDRF T1D Fund, Maryland Momentum Fund, VTC Innovation Fund and TEDCO.
– The new investment will be used to advance the development program for its lead product candidate VLX-1005 for the treatment of heparin-induced thrombocytopenia (HIT).

Source
Biotechnology Health Care Medical Device North America Pharmaceutical

RayzeBio Secures $108 Million Series C Financing to Drive Forward Its Pipeline of Targeted Radiopharmaceuticals for Cancer

– RayzeBio, Inc. announced a $108m Series C financing led by Venrock Healthcare Capital Partners alongside new investors Perceptive Advisors, Vivo Capital, Acuta Capital Partners, Deerfield Management, and TCG X.
– Also participating were all of Rayze’s existing investors: venBio Partners, Versant Ventures, Samsara BioCapital, Redmile Group, Viking Global Investors, Cormorant Asset Management, OrbiMed, LifeSci Venture Partners, Logos Capital, Alexandria Venture Investments, and others.
– The targeted radiopharmaceuticals field represents a highly clinically validated modality that, until recently, has been underappreciated.
– With over $258m of capital raised since the company first debuted in the second half of 2020, RayzeBio has rapidly expanded its team, infrastructure, capabilities, and pipeline.

Source
Biopharma Biotechnology Pharmaceutical Therapeutics Western Europe

HiFiBiO Therapeutics Closes $75M Series D

– HiFiBiO Therapeutics, a biotechnology company with expertise in immune modulation and drug intelligent science, announced the completion of an oversubscribed $75M Series D financing round.
– The funding was led by the new investor Mirae Asset Financial Group.
B Capital Group, Sherpa, Maison Capital, Trinity Innovation Fund, Grand Mount, and HKSTP Venture Fund also participated in this round.

Source
Pharmaceutical Western Europe

Actimed Therapeutics Closes £2.5M Extended Seed B Funding Round

– Actimed Therapeutics Ltd, a London, UK-based clinical stage company focused on bringing innovation to the treatment of muscle wasting disorders, with a focus on cachexia, closed its extended Seed B financing round.
– The proceeds will allow the company to further advance the development of its lead compound, S-pindolol (ACM-001.1), for cancer cachexia, by performing a Pharmacokinetic (PK) and Pharmacodynamic (PD) study due to start later this year.

Source
Biopharma Biotechnology North America Pharmaceutical

Onchilles Pharma Raises $7 Million Series A to Advance Drug Candidates to Activate Newly Discovered Broad-Acting Anticancer Pathway

– Onchilles Pharma announced a $7m Series A financing from LYZZ Capital and includes a $500k investment from the University of Chicago’s Startup Investment Fund.
– The proceeds of the financing will be used to develop first-in-class therapeutics to activate a novel pathway of the innate immune system with potential for universal anti-cancer activity, independent of genetic mutation.
– Research published in today’s issue of Cell is the first to describe this pathway where human neutrophils release catalytically active neutrophil elastase, called ELANE, to selectively kill many cancer cell types while sparing non-cancer cells.
– ELANE is an entirely new treatment paradigm with the potential to have broad and selective cancer killing activity regardless of genetic mutation or anatomical origin.

Source
Health Care North America Personal Health Pharmaceutical Wellness

Thirty Madison Raises $140M in Series C Funding

– Thirty Madison, a New York-based healthcare company that focuses on people with chronic conditions, raised $140M in Series C funding.
– The round was led by new investor HealthQuest Capital with participation from Mousse Partners and Bracket Capital and existing investors Polaris Partners, Johnson & Johnson Innovation – JJDC, Inc., Northzone, Greycroft, and others.
– The company intends to use the funds to expand access to its care model for people who suffer from chronic conditions and enhance the capabilities of its proprietary platform.

Source
Biopharma Biotechnology Mechanical Engineering Pharmaceutical Western Europe

RheaVita Closes EUR 2.5 million Series A Financing Co-Led by Novalis Biotech Acceleration and PMV

– RheaVita, a company pioneering continuous freeze-drying technology for biopharmaceutical products, announced that the company has closed a EUR 2.5 million Series A Financing.
– The round was co-led by Novalis Biotech Acceleration and Participatie Maatschappij Vlaanderen (PMV).
– Concurrent with the financing, Kjell Mortier from Novalis Biotech Acceleration and Stefan De Waele of PMV will join RheaVita’s Board of Directors.
– RheaVita has developed the world’s first end-to-end continuous freeze-drying solution to address biopharmaceutical product development, manufacturing and supply needs in order to efficiently reach patients.
– The patented RheaVita continuous freeze-drying technology integrates all the traditional freeze-drying process steps into one continuous production line.

Source
1 2 3
Crunchbase icon

Content report

The following text will be sent to our editors: